Washington, D.C. (March 2, 2020) — As part of the biopharmaceutical industry’s commitment to advance diversity and inclusion in the workplace, president and chief executive officer Stephen J. Ubl of the Pharmaceutical Research and Manufacturers of America (PhRMA) signed the CEO Action for Diversity & Inclusion Pledge. PhRMA joins over 900 businesses who have committed to this pledge.
“PhRMA has a unique ability to highlight our members’ diversity and inclusion efforts and to help our industry learn from each other on how to build stronger, more diverse workforces,” said Ubl. “This pledge shows our commitment to diversity and inclusion – both internally and in the biopharmaceutical industry – which are essential to unlocking the scientific challenges that lead to new medicines and to helping the patients we serve.”
The CEO Action Plan for Diversity & Inclusion Pledge includes four goals that PhRMA is committed to working toward:
PhRMA signed onto this pledge in tandem with work currently underway to celebrate diversity in our workforce and promote best practices across the industry. Some of these activities include:
“The pledge allows us to expand our insights on diversity and inclusion work beyond our own member companies by learning from other CEOs who have signed the pledge,” continued Ubl. “I look forward to deepening our understanding on this issue and building an even more inclusive workplace.”
Learn more about the pledge here.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $900 billion in the search for new treatments and cures, including an estimated $79.6 billion in 2018 alone.